Alamar Biosciences
PublicAlamar Biosciences is now publicly traded
The data on this page reflects Alamar Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 17, 2026
Last Round
Convertible Debt
Jan 11, 2026
Total Funding Raised
$546.12M
Company Overview
Alamar Biosciences is a biotechnology company that develops a precision proteomics platform for protein analysis and cancer detection, utilizing advanced antibody technologies to enhance disease diagnosis and facilitate early biomarker discovery for improved patient outcomes.
Sector
Biotech
Verticals
Life Sciences, LOHAS & Wellness, Oncology
AI Layer
Application
Keywords
Alamar Biosciences Comparables
Compare Alamar Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quanterix Corporation | 82% | |
| Nautilus Biotechnology | 81% | |
| Thermo Fisher Scientific Inc. | 81% | |
Alamar Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Apr 17, 2026 | ||||
| Convertible Debt | Jan 11, 2026 | ||||
| Convertible Debt | Jan 8, 2026 | ||||
| Grant | Jan 8, 2025 | ||||
| Series C | Feb 26, 2024 | ||||
Series B | Sep 8, 2021 |
Key People
Founding team and executive leadership
Alamar Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of Health and Human Services | Grant |
| Braidwell | Convertible Debt |
| Gates Ventures | Grant |
| Morningside Ventures | Series B |
| ARCH Venture Partners | Series C |
| T. Rowe Price | Convertible Debt |
| TMCP | Series C |
Alamar Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
